Targeted radiation delivered directly to brain tumor cavity in new trial

NCT ID NCT07648823

Recruiting now Disease control Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a single dose of a radioactive drug called [177Lu]Lu-XT771 in people with recurrent glioblastoma, an aggressive brain cancer. The drug is injected directly into the cavity left after tumor removal surgery, aiming to deliver radiation precisely to cancer cells while sparing healthy tissue. The study involves only 3-5 participants and focuses on safety, how the drug spreads in the body, and its potential to slow tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [177Lu]Lu-XT771 (a radioactive drug injected into the tumor cavity)
What this could lead to: If successful, this approach could provide a new, targeted treatment option for recurrent glioblastoma, potentially slowing tumor growth with fewer side effects than systemic therapies.
What could go wrong: This is a very early, small study (only 3-5 participants) designed primarily to test safety and dosing. The treatment may not shrink tumors or improve survival, and there are risks from radiation exposure to healthy brain tissue and other organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA (GBM) RECURRENT GLIOBLASTOMA RECURRENT GLIOBLASTOMA (WHO-GRADE IV GLIOMA) RECURRENT GLIOBLASTOMA, IDH-WILDTYPE

Contacts and locations

Locations

Beijing Tiantan Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100070, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.